16 November 2018
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, presented a number of compelling clinical outcomes around its flagship JOURNEY II BCS knee earlier this month at the American Association of Hip and Knee Surgeons (AAHKS). The announcement follows more than a dozen publications during the past year from various authors around the globe.1-14
In one of the largest multi-center retrospective patient cohorts ever studied, new clinical evidence represented excellent mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants including:
- About 1% of patients required major revision out to 6 years.15
- No major or minor revision of any patient four years or more post-op.15
- Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).15
- Statistically significantly better survivorship for patients under 55 when compared to the Australian registry class average for the same age group at 6 years. The revision rate was 3% at 5 years for males and 3.1% for females, compared to 7% for males and 6.9% for females reported by the AOANJRR for cemented PS TKAs.15
These data add to the growing body of evidence that JOURNEY II TKA delivers smoother patient recovery, improved functional outcomes, higher patient satisfaction and healthcare cost-savings when compared with conventional TKAs. 1,2,6,7,9,16,17
“It is very exciting to see additional clinical validation in such a large study showing excellent patient outcomes with our JOURNEY II TKA. For years we at Smith & Nephew have been discussing the unique benefits of JOURNEY II knees and we are now seeing regular publications highlighting the improved outcomes compared to conventional TKAs. These better-quality outcomes are a direct benefit to our surgeon customers and most importantly to their patients,” said Skip Kiil, President of Global Orthopaedics, Smith & Nephew.
JOURNEY II TKA first launched in late 2011 and now has more than 150,000 procedures performed worldwide.18
+1 (978) 749-1440
Smith & Nephew plc
+44 (0) 1923 477314
Smith & Nephew plc
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).